ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.PloS one · 2017Pooled it
- A complex role of chromogranin A and its peptides in inflammation, autoimmunity, and infections.Frontiers in immunology · 2025Review
- Single-cell transcriptome analysis of the novel coronavirus (SARS-CoV-2) associated gene ACE2 expression in normal and non-obstructive azoospermia (NOA) human male testes.Science China. Life sciences · 2020Article
- Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: data from the Osteoarthritis Initiative.Annals of the rheumatic diseases · 2019Article
- Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review.Cell death discovery · 2019Review
- Combined detection of dickkopf-1 subtype classification autoantibodies as biomarkers for the diagnosis and prognosis of non-small cell lung cancer.OncoTargets and therapy · 2017Article
- Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease.Mediators of inflammation · 2016Review
- A network-based method to evaluate quality of reproducibility of differential expression in cancer genomics studies.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated autoantibodies show promise as sensitive biomarkers for the early detection of cancer. To test the immunogenicity of chromogranin A (ChgA) as a B cell autoantigen and to assess the potential applications of ChgA autoantibodies as novel biomarkers for the diagnosis of non-small cell lung cancer (NSCLC), we developed a high-content peptide microarray using ChgA peptides. Autoantibody profiling was carried out using sera from 168 individuals with NSCLC and 97 healthy controls. We present evidence for the occurrence of autoantibodies to ChgA peptides in patient sera and identified five highly responsive peptides in the NSCLC group using significance analysis of microarray (SAM). Receiver operating characteristic analyses showed that ChgA autoantibodies are valuable in the predictive diagnosis of NSCLC, suggesting that serum autoantibodies to ChgA-derived peptides are promising novel markers of NSCLC. Moreover, the high-content peptide microarray antibody profiling reported in this work provides a powerful tool to visualize the overall B cell response to ChgA peptides and should enable the rapid development of in-depth research into ChgA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.